Yesterday, the “Tape-Bomb” in Chief caused a kerfuffle in pharma/biotech stocks after saying that drug companies are “getting away with murder” on pricing. Few, beside drug co execs, lobbyists and major shareholders would disagree with …
Continue readingXBI
Yesterday I discussed the sector rotation since the presidential election results on Nov 9th: I sincerely have no idea whether the rotation out of growth stocks, primarily Tech, and “yield-ers”… Consumer Staples, Telco and Utilities, …
Continue reading
Biotech and Healthcare stocks are down a couple percent today after an epic bounce following the surprise outcome of the presidential election. A few weeks ago we detailed defined risk trade ideas in the S&P …
Continue readingWith the election results decided, and the market not down the 5% it was as indicated by the futures last night, you may be forgiven for thinking that we basically have market status quo from yesterday’s …
Continue readingCurrent polls point to Hillary Clinton being sworn in as our next President of the United States on January 20th. As far as what that means for policy, Clinton is a typical left of center …
Continue reading
Biotech stocks have been a disaster so far in 2016, with Nasdaq Biotech etf IBB down 20% ytd, and down 34% from its all time highs (in August 2015), and S&P Biotech etf XBI down …
Continue reading
The S&P 500 (SPX) clawed back a good bit of its early 1% losses by days end. One noticeable theme in today’s trading was options traders rolling existing positions: GS: bank stocks under-performed the broad market most of the day, with …
Continue reading
We’re not getting to hear much policy discussion in this strange presidential election cycle but one topic that sometimes gets through is healthcare. A hot button issue over the past year on the Democratic presidential …
Continue reading
By now we probably sound like a broken record when it comes to unusual options activity. But for the post I am going to write, our usual disclaimer makes a ton of sense: without intimate …
Continue readingDespite the S&P 500 (SPX) very near all time highs, up nearly 7% on the year, Biotech stocks are one of the only S&P sectors down on the year, with the S&P Biotech etf (XBI) down a whopping …
Continue reading